Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132989 | 0.86 | WDR5 (0.44) | CA2ALDH1A1KDM4EWDR5CES1 | |
| SCHEMBL29382484 | 0.86 | WDR5 (0.44) | CA2ALDH1A1KDM4EWDR5CES1 | |
| SCHEMBL14596131 | 0.79 | CA1 (0.39) | SLC22A12CA1CA2ALDH1A1KDM4E | |
| SCHEMBL13948301 | 0.79 | CA1 (0.53) | SLC22A12CA1CA2ALDH1A1KDM4E | |
| SCHEMBL4403131 | 0.78 | MAPT (0.43) | ALDH1A1KDM4EWDR5POLBHPGD | |
| SCHEMBL12336891 | 0.78 | MAPT (0.43) | ALDH1A1KDM4EWDR5POLBHPGD | |
| SCHEMBL6053369 | 0.78 | WDR5 (0.38) | ALDH1A1KDM4EHSP90AA1HSP90AB1WDR5 | |
| SCHEMBL7025867 | 0.78 | KMT2A (0.42) | ALDH1A1KDM4EHSP90AA1HSP90AB1WDR5 | |
| SCHEMBL19884356 | 0.78 | WDR5 (0.38) | ALDH1A1KDM4EWDR5CES1DNMT1 | |
| SCHEMBL11991070 | 0.78 | WDR5 (0.38) | ALDH1A1WDR5CES1DNMT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910744-B2 | Pyrazole and Pyrimidine groups are introduced on aromatic phosphine; (3-bromophenyl)methyl ketone and ethylene glycol cyclize to [3-(2-methyl-1,3-dioxolane-2-yl)phenyl]diphenylphosphane; adding hydrazine monohydrate, then oxidizing with hydrogen peroxide; [3-(3-Pyrazolyl)phenyl]diphenylphosphane oxide | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENT II KG (DE) | 2011-03-22 | — | — | US | disclosed |
| US-20080221335-A1 | Method for the Manufacture of Substituted Phosphanes, and Substituted Phosphanes Manufactured According to Said Method | ZYLUM BETEILIGUNGSGESELLSCHAFT MBH & CO. PATENTE II KG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1469004-B1 | Method for preparing aminophosphines and aminophosphine oxides, intermediates therefor | TAKASAGO PERFUMERY CO LTD (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1013658-B1 | Aminophosphine-metal complex for asymmetric reactions | TAKASAGO PERFUMERY CO LTD (JP) | 2004-11-03 | — | — | EP | disclosed |
| EP-1469004-A1 | Method for preparing aminophosphines and aminophosphine oxides, intermediates therefor | Takasago International Corporation (JP) | 2004-10-20 | — | — | EP | disclosed |
| US-6515156-B2 | Stereoselective, efficient catalyst for synthesis of enantiomerically pure compounds; comprising compex of transition metal and aminophosphine ligand | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| US-6388130-B2 | ALKALINE HYDROGEN PEROXIDE TO OXIDIZE 2-CYANO-2'-DIARYL PHOSPHINYL-1,1'-BINAPHTHYL TO OBTAIN A 2-AMIDO DERIVATIVE, REACTED WITH A METAL ALKOXIDE AND BROMINE IN AN ALCOHOL TO A 2-SEC-AMINO DERIVATIVE; TRANSITION METAL COMPLEX CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20010047110-A1 | Method for producing axial asymmetric compounds, intermediates for producing the same, complexes of transition metals with novel axial asymmetric compounds as the ligands, catalysts for asymmetric hydrogenation, and catalysts for forming asymmetric carbon-carbon bonds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-11-29 | — | — | US | disclosed |
| US-6323353-B1 | USED AS CATALYST FOR ASYMMETRIC HYDROGENATION OR CARBON-CARBON BOND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-11-27 | — | — | US | disclosed |
| US-20010037033-A1 | Method for producing axial asymmetric compounds, intermediates for producing the same, complexes of transition metals with novel axial asymmetric compounds as the ligands, catalysts for asymmetric hydrogenation, and catalysts for forming asymmetric carbon-carbon bonds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-1013658-A1 | Aminophosphine-metal complex for asymmetric reactions | Takasago International Corporation (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047110-A1 | Method for producing axial asymmetric compounds, intermediates for producing the same, complexes of transition metals with novel axial asymmetric compounds as the ligands, catalysts for asymmetric hydrogenation, and catalysts for forming asymmetric carbon-carbon bonds | CORO1C, AP3M1, ARL1 | SLC22A12 4466/4885CA1 450/4885CA2 670/4885 |
| US-20080221335-A1 | Method for the Manufacture of Substituted Phosphanes, and Substituted Phosphanes Manufactured According to Said Method | SCLY, SELENOI, TST | SLC22A12 1769/4885CA1 443/4885CA2 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.